Table 4.
Ongoing clinical trials targeting TP53 mutant and wild-type AML.
| Target | Clinical trial number | Phase | Trial status | Small molecule | Antineoplastic combination |
|---|---|---|---|---|---|
| Mutant TP53 | NCT03072043 | IB/II | Recruiting | APR-246 | Azacitidine |
| MDM2 |
NCT01773408 NCT02098967 NCT02545283 NCT03671564 NCT02319369 NCT03634228 NCT03041688 NCT02143635 |
I/IB I III I I I/II IB I |
Completed Completed Recruiting Recruiting Recruiting Recruiting Recruiting Recruiting |
Idasanutlin/Cometinib Milademetan AMG-232 HDM201 |
Cytarabine Alone or with Azacitidine Cytarabine Decitibine |
| MDM2 and BCL-2 | NCT02670044 | IB/II | Recruiting | Dasanutlin/Venetoclax | |
| MDM2 and MDMX | NCT02909972 | I | Recruiting | ALRN-6924 | Alone or Azacitidine |
| HMG-CoA reductase | NCT03560882 | I | Recruiting | Atorvastatin | |
| Several targets | NCT03381781 | II | Recruiting | Arsenic Trioxide | Decitabine |